In the second quarter, 32 new shares and 20 additional shares were purchased

Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors

Europe’s reindustrialization is creating new opportunities for Chinese companies. However, the winners will not necessarily be those seeking quick acquisitions or rapid market access. The real opportunities belong to companies capable of embedding themselves into Europe’s industrial ecosystem and supporting the long-term transformation of local industries.

From Paris to Shanghai: The Same Project, Two Different Views of Time

In Europe-China industrial cooperation, misunderstandings often start with time. Chinese companies may see European decision-making as slow. European companies may see Chinese execution as rushed. Yet very often, neither side is wrong. They are responding rationally to different ecosystems, different levels of system interdependence and different views of risk.

Futurtec Adds CE MDR-Certified Knee-Replacement System to Its Orthopedic Robotics Portfolio

Futurtec（鑫君特）has received European Union Medical Device Regulation certification for its ORTHBOT X knee-replacement surgical navigation and positioning system, according to a company announcement reported by MedChina in August.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.